Featured Education

Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches

Click here to learn more

Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients

Click here to learn more

Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders

Click here to learn more

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Click here to learn more

Expanding Therapy Options for the Treatment of Relapsed or Refractory Multiple Myeloma: BCMA-Directed Therapies

Click here to learn more

Build Your Own Case Study | Obesity: Treating the Whole Patient

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Episode 1 of 4 - The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC
  • Credit: 0.30hr(s)
  • NCPD
  • November 22, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
Biomarker testing can have a significant impact on the treatment plan of patients with non-small cell lung cancer (NSCLC).  In this first episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care, expert faculty apply the latest clinical guidelines and give practical tips on breaking down barriers for oncology teams to successfully implement biomarker testing for NSCLC patients, including those in underserved populations.
Enroll Today
View Course
  • On-Demand
Episode 3 of 3 - Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • December 1, 2022 — 
  • December 14, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
  • Location: Internet Activity Enduring
In the advent of novel targeted therapies for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), clinicians must consider the potential of adverse events (AEs) that can affect patient outcomes. In the last episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, our expert faculty will engage in an interactive discussion on AE-management to promote optimal treatment-decision making for clinicians. In addition, learn tips to on how to counsel your patients on monitoring their symptoms to support timely and effective care.
Enroll Today
View Course
  • On-Demand
Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 8, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
Treatment strategies for relapsed/refractory multiple myeloma (RRMM) are inevitably complex as oncology teams must consider patient-, treatment-, and disease-related factors in their decision-making. Tune into the last episode of the Med Table Talk® Series on Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy
Enroll Today
View Course
  • On-Demand
Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • January 26, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss: The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies Prevention and management strategies for adverse events associated with BCMA agents The unmet need for representation in clinical trials
Enroll Today
View Course
  • On-Demand
Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • February 17, 2023 — 
  • February 16, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: NSCLC, Oncology
  • Location: Internet Activity Enduring
This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points to metastatic NSCLC (mNSCLC) patient cases while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in mNSCLC and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 1 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies for an in-depth dive into the data!
Enroll Today
View Course
  • On-Demand
DIABESITY DIALOGUES: Patient Perspectives for PCPs - Tackling the Treatment Paradigms of Obesity, T2D, and Other Metabolic Disorders
  • Credit: 1.00hr(s)
  • AAPA, CDCES, CME, CPE, IPCE, NCPD
  • June 9, 2023 — 
  • June 8, 2024
  • Therapeutic Areas: Diabetes, Obesity
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
There is an urgent need for effective intervention by healthcare professionals (HCPs) to address the twin epidemics of Type 2 diabetes (T2D) and obesity. Tune into the Diabesity Dialogues vodcast, where renowned physicians, Dr. Robert Kushner, MD, and Dr. Jamy Ard, MD, provide valuable insights on treatment initiation, intensification, and the effective management of diabesity in the presence of other comorbidities. Hear how our esteemed hosts harness the power of social media and discuss the latest information on GLP-1 receptor agonists (RA) and dual GIP/GLP-1 RAs and dispel potential misinformation. In this special feature, tune into patient voices from social media and learn practical tips to enhance patient-centered care and be at the forefront of transformative practices. Don’t miss this opportunity to join this cutting-edge conversation.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top